Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with pd-l1 of >= 50%: the empower-lung 1 study

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorwosidSadettin Kılıçkap / DXP-4273-2022en_US
dc.contributor.authorGumus, Mahmut
dc.contributor.authorChen, Chieh I.
dc.contributor.authorIvanescu, Cristina
dc.contributor.authorBondarenko, Igor
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2022-11-11T08:06:27Z
dc.date.available2022-11-11T08:06:27Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground In the EMPOWER-Lung 1 trial (, NCT03088540), cemiplimab conferred longer survival than platinum-doublet chemotherapy for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%. Patient-reported outcomes were evaluated among trial participants. Methods Adults with NSCLC and Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned cemiplimab 350 mg every 3 weeks or platinum-doublet chemotherapy. At baseline and day 1 of each treatment cycle, patients were administered the European Organization for Research and Treatment of Cancer Quality of Life-Core 30 (QLQ-C30) and Lung Cancer Module (QLQ-LC13) questionnaires. Mixed-model repeated measures analysis estimated overall change from baseline for PD-L1 >= 50% and intention-to-treat populations. Kaplan-Meier analysis estimated time to definitive deterioration. Results In PD-L1 >= 50% patients (cemiplimab, n = 283; chemotherapy, n = 280), baseline QLQ-C30 and QLQ-LC13 scores showed moderate-to-high functioning and low symptom burden. Change from baseline favored cemiplimab on global health status/quality of life (GHS/QOL), functioning, and most symptom scales. Risk of definitive deterioration across functioning scales was reduced versus chemotherapy; hazard ratios were 0.48 (95% CI, 0.32-0.71) to 0.63 (95% CI, 0.41-0.96). Cemiplimab showed lower risk of definitive deterioration for disease-related (dyspnea, cough, pain in chest, pain in other body parts, fatigue) and treatment-related symptoms (peripheral neuropathy, alopecia, nausea/vomiting, appetite loss, constipation, diarrhea) (nominal p < .05). Results were similar in the intention-to-treat population. Conclusions Results support cemiplimab for first-line therapy of advanced NSCLC from the patient's perspective. Improved survival is accompanied by improvements versus platinum-doublet chemotherapy in GHS/QOL and functioning and reduction in symptom burden.en_US
dc.identifier.citationGümüş, M., Chen, C. I., Ivanescu, C., Kilickap, S., Bondarenko, I., Özgüroğlu, M., ... & Sezer, A. (2022). Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of≥ 50%: The EMPOWER‐Lung 1 study. Cancer.en_US
dc.identifier.doi10.1002/cncr.34477en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.scopus2-s2.0-85141409577en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://dx.doi.org/10.1002/cncr.34477
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3319
dc.identifier.wosWOS:000875663600001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherWILEYen_US
dc.relation.ispartofCANCERen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCemiplimaben_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectPatient-Reported Outcomesen_US
dc.subjectSymptom Burdenen_US
dc.titlePatient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with pd-l1 of >= 50%: the empower-lung 1 studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Cancer - 2022 - G m - Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non small.pdf
Boyut:
893.99 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu